 This is partly because of high intracellular levels of its triphosphate metabolite reached in cells.Clinical trials of elvucitabine are on hold, because it has shown bone marrow suppression in some patients, with CD4+ cell numbers dropping as early as two days after initiation of dosing.Amdoxovir is a guanosine analogue NRTI prodrug that has good bioavailability.